NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2032220252

Registered date:08/08/2022

Feasibility Clinical Trial in PKR-001

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedhyperphosphatemia
Date of first enrollment26/07/2022
Target sample size40
Countries of recruitment
Study typeInterventional
Intervention(s)In the treatment group, PKR-001 is placed and treated at every hemodialysis session together with a dialyzer.

Outcome(s)

Primary OutcomeSerum phosphorus levels at 24 weeks Safety (adverse events, Adverse Device Effect, bone density)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 85age old
GenderBoth
Include criteria(1) Patients who fulfill the following conditions for at least one month prior to obtaining consent -Taking more than 2 phosphorus adsorbents without any change in dosage and administration -No change in diet therapy -Patients have been receiving hemodialysis 3 times a week without any change in dialysis conditions (dialyzer, dialysate). -If osteoporosis drugs or calcimimetics are prescribed, the patient is taking them without any change in dosage and administration. (2) Patient has a serum phosphorus level of 6.0 mg/dL or higher within 1 month prior to obtaining consent (3) Patients who have been on hemodialysis for more than 3 months (4) Patients who are between 20 and 85 years of age on the date of consent
Exclude criteria(1) Patients who have undergone parathyroid intervention [parathyroidectomy (PTx), percutaneous ethanol injection therapy (PEIT), etc.] within 1 year prior to obtaining consent or are scheduled to undergo such intervention during the trial (2) Patients with NYHA classification III or IV cardiac disease (3) Patients with AS severity classified as severe or very severe aortic stenosis (4) Patients with severe carotid artery stenosis (stenosis rate >= 70%) (5) Patients who are pregnant or lactating and wish to become pregnant during the study period (6) Patients who are unable to consent to an appropriate contraceptive method (7) Patients who are judged by the investigator/approved investigator to be unable to complete the observation during the study period (8) Patients with allergies that are medically difficult to control, as determined by the investigator/approved investigator (9) Other patients whom the investigator/approved investigator judges to be difficult to treat with the investigational device

Related Information

Contact

Public contact
Name Shimpei Terada
Address 2-3-18, Nakanoshima, Kita-ku Osaka Osaka Japan 530-8288
Telephone +81-50-3181-4126
E-mail Shimpei.Terada@kaneka.co.jp
Affiliation KANEKA CORPORATION
Scientific contact
Name Makoto Kuro-o
Address 3311-1 Yakushiji Shimotsuke-shi, Tochigi Tochigi Japan 329-0498
Telephone +81-285-58-7449
E-mail mkuroo@jichi.ac.jp
Affiliation Jichi Medical University